{"filings":[{"id":2225558,"accession_number":"0001193125-26-347400","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2026-08-12T23:35:50+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cullinan's zipalertinib combo meets PFS endpoint in Phase 3 REZILIENT3 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["REZILIENT3 Phase 3 trial (285 patients) met primary endpoint of PFS at planned interim analysis; statistically significant and clinically meaningful improvement.","Zipalertinib plus platinum-based chemotherapy vs chemo alone in first-line EGFR exon 20 insertion NSCLC; safety manageable.","Independent Data Monitoring Committee recommended unblinding; trial continues for efficacy/safety monitoring.","Taiho and Cullinan plan to pursue U.S. FDA approval for the combination in first-line setting pending discussions.","Full results to be submitted for presentation at an upcoming international medical conference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2088124,"accession_number":"0001193125-26-336700","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2026-08-06T11:06:30+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cullinan Therapeutics Q2 2026 net loss $53.7M; cash $356M; pipeline on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $53.7M vs $70.1M YoY; R&D expenses $44.4M vs $61.0M; G&A $12.8M vs $14.8M.","Cash and investments $356M as of June 30, 2026; runway into 2029.","CLN-049 Phase 2 in R/R AML to start Q3 2026 after positive FDA End-of-Phase 1 meeting.","CLN-978 multi-dose data in RA Q3 2026, SLE Q4 2026; Phase 2 expansion early 2027.","Zipalertinib NDA accepted; PDUFA Feb 27, 2027; Cullinan eligible for $30M on 2L approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1086278,"accession_number":"0001193125-26-272890","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2026-06-16T21:18:15+00:00","items":["5.07"],"status":"ready","headline":"Cullinan Therapeutics reports annual meeting results; all proposals approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders elected Nadim Ahmed and Stephen Webster as Class III directors for three-year terms.","Ratified KPMG LLP as independent auditor for fiscal year 2026 with 53.7M votes for, 36.8K against.","Advisory vote on executive compensation approved with 48.5M for, 1.1M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":954917,"accession_number":"0001193125-26-264916","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2026-06-10T11:32:05+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cullinan Therapeutics reports positive clinical data for CLN-978 and velinotamig in autoimmune diseases","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CLN-978 achieved DAS28-ESR remission in a rituximab-refractory RA patient, reducing score from 4.0 to 2.2 at week 4.","First three SLE patients on CLN-978 multi-dose showed safety consistent with EULAR 2026 data; rapid proteinuria improvement supports lupus nephritis trial.","Velinotamig (BCMA TCE) induced complete renal responses in two SLE patients; SLEDAI-2K scores dropped to 0 and 2 at week 8.","Cullinan plans Phase 2a expansion for CLN-978 in lupus nephritis in early 2027 and Phase 1/2a for velinotamig in autoimmune cytopenias in Q1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":899876,"accession_number":"0001193125-26-260640","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2026-06-08T10:32:15+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cullinan presents initial Phase 1 CLN-978 data in SLE and RA at EULAR; 71% SLE response rate, 5 DORIS remissions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In SLE (n=18), 10 of 14 patients (71%) with ≥4 weeks follow-up achieved ≥4-point hSLEDAI reduction; 5 attained DORIS remission.","In RA (n=11), disease activity improved in 5 of 7 evaluable patients (71%), including one DAS28-ESR remission at 30 µg target dose.","Peripheral B-cell depletion >80% in 82% of SLE patients; BLOQ depletion in 50% at target doses ≥20 µg. Dose-dependent depletion also seen in tissues.","CRS events in 11 of 29 patients (38%); mostly Grade 1. One Grade 3 CRS at 45 µg dose led to cohort discontinuation; no ICANS observed.","Company to host Immunology Day June 10 with additional CLN-978 multi-dose data and initial velinotamig data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":501837,"accession_number":"0001193125-26-229173","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2026-05-18T21:30:08+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cullinan reports initial Phase 1 data for CLN-978: B cell depletion and early efficacy in RA/SLE","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["As of Jan 14, 2026 cutoff, 14 patients dosed (5 RA, 9 SLE) across cohorts 1-3.","B cell depletion >75% in 9/11 patients after 10 mcg; 3/6 below quantification after 20 mcg.","4/5 RA patients had DAS28-ESR decrease from high activity to moderate/remission.","5/6 SLE patients had SLEDAI score decrease >4 points; ultrasound synovitis improved in 3/4 RA.","CLN-978 well tolerated; dose escalation continues; updated data at EULAR June 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95479,"accession_number":"0001193125-26-210290","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cullinan Therapeutics Q1 net loss $49.7M, cash $393.3M; zipalertinib NDA accepted with PDUFA Feb 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $49.7M for Q1 2026 vs $48.5M in Q1 2025; R&D expense $42.1M, G&A $11.6M.","Cash and investments $393.3M as of March 31, 2026; runway into 2029 under current plan.","FDA accepted NDA for zipalertinib in EGFR ex20ins NSCLC; PDUFA target date February 27, 2027.","Initial CLN-978 SLE and RA data to be presented at EULAR June 6, 2026; multi-dose RA data due Q3 2026.","Velinotamig initial SLE data expected Q4 2026; CLN-049 RP2D and AML update planned by Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108594,"accession_number":"0001193125-26-099355","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cullinan reports $439M cash, $219.9M net loss; CLN-978 data and zipalertinib NDA on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments of $439.0M as of Dec 31, 2025; runway into 2029.","Net loss of $50.7M in Q4 2025 ($219.9M full year), vs $47.6M in Q4 2024.","Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA in Q3 2026.","Zipalertinib rolling NDA submission completed; REZILIENT3 frontline study enrollment completed, top-line results by year-end 2026.","Cullinan eligible for $30M upon 2L U.S. approval, up to $100M upon 1L, plus 50/50 profit share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108593,"accession_number":"0001193125-26-006998","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Cullinan reports $439M cash as of Dec 31, 2025; outlines 2026 clinical milestones for CLN-978, CLN-049, zipalertinib","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, equivalents, investments, interest receivable $439.0M at Dec 31, 2025; runway into 2029.","CLN-978: Phase 1 dose escalation in RA, SLE, SjD ongoing; initial data readouts in Q2/Q3/Q4 2026.","CLN-049: Fast Track for relapsed/refractory AML; dose expansion to determine RP2D in Q4 2026; pivotal trial expected.","Zipalertinib: NDA submission completion expected Q1 2026; REZILIENT3 enrollment complete H1 2026; $130M US milestones + 50% profit share.","Velinotamig: Genrix Bio Phase 1 in China initiated; initial data in Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125038,"accession_number":"0001193125-25-310764","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cullinan Therapeutics reports 31% CR/CRh rate at 12 µg/kg for CLN-049 in R/R AML Phase 1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At 12 µg/kg (n=16), CR/CRh rate 31% (5/16) and CRc rate 31% (5/16); at ≥6 µg/kg (n=32), CR/CRh 25% and CRc 28%.","In TP53-mutated AML patients at 12 µg/kg, 50% (4/8) achieved CR/CRh; 3 of 4 responses durable >16 weeks.","63% (5/8) of responders at ≥6 µg/kg had response >16 weeks; 2 patients proceeded to transplant.","Safety: CRS mostly Grade 1/2 (35.6%), no Grade 3 with two step-up doses; no discontinuations due to CRS.","FDA granted Fast Track designation; dose escalation continues with expansion cohorts planned early 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125037,"accession_number":"0001193125-25-291448","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Cullinan Therapeutics terminates exclusive MIT license for CLN-617; program abandoned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminates Exclusive Patent License Agreement with MIT for CLN-617, effective Feb 18, 2026.","Decision based on not pursuing further development of CLN-617 cancer immunotherapy.","Company will return licensed patent rights for CLN-617 technology to MIT.","CLN-617 was an exclusive worldwide license for a cancer immunotherapy product."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125036,"accession_number":"0001193125-25-268041","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Cullinan Q3 net loss $50.6M; focuses on T cell engagers; cash runway into 2029","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $50.6M vs $40.6M YoY; R&D expense $42.0M, G&A $13.6M.","Cash & investments $475.5M at Sept 30, 2025; runway expected into 2029.","CLN-049 showed ~30% CRc in R/R AML; oral presentation at ASH 2025.","CLN-978 initial SLE & RA safety/B-cell data expected H1 2026.","Discontinued CLN-619 and CLN-617; partner Taiho plans NDA for zipalertinib by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125035,"accession_number":"0001193125-25-261799","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cullinan reports Phase 1 CLN-049 data: 31% CRc at 12 μg/kg in r/r AML","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Anti-leukemic activity at doses ≥6 μg/kg: CRc 30%, ORR 57% (n=23); at 12 μg/kg CRc 31%, ORR 69% (n=13).","Responses across genetic risk; in TP53-mutated AML 4/5 patients responded (2 CRh, 2 MLFS) at 12 μg/kg.","Safety manageable: all CRS Grade 1-2; no discontinuations due to CRS or ICANS. Common TEAEs: CRS 40%, IRR 35%.","Oral presentation at ASH on Dec 8, 2025; dose escalation ongoing. Company to host investor event Dec 8."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141731,"accession_number":"0000950170-25-112949","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cullinan Therapeutics revises CLN-978 SLE data timing to H1 2026","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Initial clinical data for CLN-978 in systemic lupus erythematosus now expected in first half of 2026.","Timelines for all other pipeline programs remain unchanged.","Updated corporate presentation posted to company website; no other changes disclosed in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141730,"accession_number":"0000950170-25-104547","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Cullinan Q2 net loss $70.1M, cash $510.9M; appoints new directors; CLN-978 enrolling","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 net loss $70.1M vs $42.0M; R&D expenses $61.0M vs $36.3M; cash and investments $510.9M providing runway into 2028.","Board changes effective Aug 7: Anne-Marie Martin and David Ryan resigned; Mittie Doyle and Andrew Allen appointed as Class I and II directors, respectively.","CLN-978 Phase 1 studies in SLE, RA, and Sjögren's actively enrolling; initial SLE safety and B cell depletion data expected Q4 2025.","Velinotamig (BCMAxCD3 T cell engager) in-licensed from Genrix Bio for $20M upfront; up to $692M in milestones plus tiered royalties.","Partner Taiho plans to submit NDA for zipalertinib in relapsed EGFR ex20ins NSCLC by end of 2025 based on REZILIENT1 pivotal data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159635,"accession_number":"0000950170-25-085425","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cullinan Therapeutics annual meeting results: all proposals pass, directors elected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Class II directors: Anthony Rosenberg, David P. Ryan, Mary Thistle; each received >47M votes for.","Ratified KPMG as independent auditor for FY2025: 51.9M for, 157K against, 14K abstain.","Approved advisory say-on-pay on executive compensation: 46.96M for, 2.00M against, 14.7K abstain.","Stockholders voted for annual say-on-pay frequency (48.5M for 1 year); board adopts annual vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159634,"accession_number":"0000950170-25-081601","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Cullinan licenses BCMAxCD3 bispecific velinotamig from Genrix for $20M upfront, up to $692M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront license fee of $20 million; Genrix eligible for up to $292M in development/regulatory milestones and up to $400M in sales-based milestones.","Tiered royalties on ex-Greater China net sales ranging from mid-single digit to mid-teens percent.","Velinotamig has shown potential best-in-class efficacy in ~50 relapsed/refractory multiple myeloma patients; Cullinan to develop in autoimmune diseases.","Genrix plans Phase 1 autoimmune study in China by end of 2025; Cullinan will conduct global development after that.","Cullinan reiterates cash runway into 2028 based on current operating plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159633,"accession_number":"0000950170-25-066382","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cullinan Q1 net loss $48.5M; CLN-978 gains EMA approval for RA, expands into Sjögren's","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $48.5M in Q1 2025 vs $37.1M in Q1 2024; R&D expenses rose to $41.5M.","Cash and investments $567.4M as of March 31, 2025; runway into 2028 reaffirmed.","EMA approved Phase 1 study of CLN-978 in active, difficult-to-treat rheumatoid arthritis; to start Q2 2025.","CLN-978 Phase 1 in Sjögren's disease to initiate in U.S. in Q2 2025; SLE data expected Q4 2025.","CLN-619 discontinued in gynecological cancers; zipalertinib REZILIENT1 results at ASCO June 1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178008,"accession_number":"0000950170-25-028343","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cullinan Therapeutics reports Q4/FY 2024 results; zipalertinib pivotal study met endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments of $606.9M at Dec 31, 2024; runway extended into 2028.","Net loss of $47.6M in Q4 2024 (vs $23.8M Q4 2023); FY 2024 net loss $167.4M (vs $153.2M).","R&D expenses $40.5M Q4 2024 (vs $34.8M); G&A $14.6M (vs $10.6M) year-over-year.","Zipalertinib Phase 2b met primary endpoint (ORR); full results mid-2025; NDA submission planned H2 2025.","Initial CLN-978 SLE data expected Q4 2025; CLN-619 endometrial/cervical cancer data expected Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178007,"accession_number":"0000950170-25-010199","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cullinan's zipalertinib meets primary endpoint in Phase 2b NSCLC trial; H2 2025 FDA submission planned","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["REZILIENT1 trial met primary endpoint of overall response rate in NSCLC with EGFR exon 20 insertion mutations after prior therapy.","Safety profile generally consistent with previous data presentations; full results to be submitted for upcoming medical conference.","Pending FDA discussions, companies plan to submit for U.S. regulatory approval in second half of 2025.","Zipalertinib (CLN-081/TAS6417) is a monotherapy for patients who have received prior therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194696,"accession_number":"0000950170-24-122778","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cullinan Therapeutics Q3 net loss $40.6M; cash $639M; CLN-978 IND cleared for SLE Phase 1","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $40.6M ($0.69/sh) vs $39.2M ($0.91/sh) in Q3 2023; cash $639M provides runway to 2028.","CLN-978 (SLE) IND cleared in US and Australia; Phase 1 starts; initial data expected Q4 2025.","Zipalertinib pivotal Phase 2b enrollment completed ahead of schedule; results mid-2025.","CLN-619 expansion data in endometrial/cervical cancers expected Q2 2025; patent issued to 2041.","R&D expense $35.5M, G&A $13.3M; both increased YoY from $33.8M and $11.0M respectively."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194695,"accession_number":"0000950170-24-114841","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cullinan Therapeutics receives FDA IND clearance for CLN-978 in moderate-to-severe SLE","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for CLN-978, a CD19 T cell engager, in systemic lupus erythematosus.","Phase 1 trial will enroll patients with SLEDAI score ≥8 and inadequate response to ≥2 prior treatments.","Starting dose 10 mcg; Part A dose escalation, Part B dose expansion with multiple schedules.","First development-stage CD19 T cell engager to receive FDA IND clearance in autoimmune diseases.","Global trial already cleared in Australia (NCT06613360); U.S. enrollment now allowed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210998,"accession_number":"0000950170-24-107011","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cullinan Therapeutics receives Australian HREC approval to start Phase 1 SLE trial of CLN-978","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["HREC approval in Australia to initiate global Phase 1 trial of CLN-978 for systemic lupus erythematosus (SLE).","CLN-978 is a CD19xCD3 bispecific T cell engager designed for off-the-shelf access and convenient dosing.","SLE affects ~430,000 people globally; current treatments rarely induce treatment-free remission.","Company also submitted IND to U.S. FDA for this study on September 16, 2024.","Trial will assess safety, pharmacokinetics, and initial clinical activity in multiple countries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210997,"accession_number":"0000950170-24-093314","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cullinan Q2 net loss $42M; cash $664.9M; advancing CLN-978 IND in SLE for Q3 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $42.0M vs $32.2M Q2 2023; R&D $36.3M, G&A $13.8M; cash runway into 2028.","CLN-978 (CD19xCD3 T cell engager) IND for SLE on track for Q3 2024; pursuing RA with FAU Erlangen & Università Cattolica.","CLN-619 combo data at ASCO showed objective responses in oncogenic mutation NSCLC; expansion cohorts added.","Positive initial zipalertinib data from REZILIENT1 study; ESMO presentation planned.","Discontinued CLN-418; returned rights to Harbour BioMed. Oversubscribed PIPE raised $280M in April."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229477,"accession_number":"0000950170-24-078554","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cullinan Therapeutics stockholders elect Anne-Marie Martin and David Meek as directors, ratify KPMG as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Anne-Marie Martin elected with 25,054,060 votes for, 11,471,277 withheld, 4,156,894 broker non-votes.","David Meek elected with 36,409,849 votes for, 115,488 withheld, 4,156,894 broker non-votes.","KPMG LLP ratified as independent auditor for FY2024 with 40,163,993 for, 516,975 against, 1,263 abstentions.","Annual meeting held June 26, 2024; no other proposals were considered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229476,"accession_number":"0000950170-24-067662","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cullinan reports Phase 2b zipalertinib data: 39% ORR in post-amivantamab NSCLC patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORR of 39% (confirmed) and DCR of 94% in 18 evaluable patients; median DOR and PFS not yet reached.","No grade 4 or 5 treatment-related adverse events; safety profile manageable and consistent with prior data.","Data cut-off Jan 12, 2024; patients received median 3 prior therapies including chemo, anti-PD1/L1, and EGFR TKI.","Enrollment in pivotal REZILIENT1 trial (Modules B2 and C) on track to complete by end of 2024.","Partnership with Taiho: upfront $275M plus up to $130M in milestones; 50/50 US profit share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229475,"accession_number":"0000950170-24-064025","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cullinan announces CLN-619+Keytruda shows PRs in EGFR/ALK NSCLC; monotherapy CR in parotid","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Combination with pembrolizumab: 3 confirmed PRs in NSCLC (EGFR/ALK) and gastric patients typically CPI-unresponsive.","Monotherapy: 1 CR (mucoepidermoid parotid, 71 wks), 2 PRs (endometrial), 9 SD ≥18 wks; clinical benefit rate 41.4%.","Safety profile well tolerated; most TRAEs grade 1/2; no treatment-related deaths.","Based on data, expansion cohorts in NSCLC initiated; Phase 1 in relapsed/refractory multiple myeloma planned.","Data to be presented at ASCO 2024 on June 3; investor event June 1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229474,"accession_number":"0000950170-24-060481","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Cullinan Q1 net loss $37.3M; cash $434.8M; plans CLN-978 autoimmune IND Q3 2024; Meek appointed director","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, investments $434.8M as of March 31, 2024; plus $280M April private placement extends cash runway into 2028.","Q1 net loss $37.3M vs $58.1M Q1 2023; R&D expenses $30.6M, G&A $12.3M.","CLN-978 development pivoted to autoimmune diseases; IND for SLE expected Q3 2024; B-NHL study discontinued.","David Meek appointed to board effective May 15; Thomas Ebeling to resign June 26.","Initial CLN-619 combination & monotherapy data to be presented at ASCO June 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229473,"accession_number":"0000950170-24-049436","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Cullinan Therapeutics hires Mary Kay Fenton as CFO; $495k salary, 200k-share option grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mary Kay Fenton appointed CFO effective April 29, 2024; previously CFO of Talaris Therapeutics.","Annual base salary set at $495,000; target annual bonus of 40% of base salary.","Received option to purchase 200,000 shares vesting over 4 years (25% one-year cliff).","Severance: 9 months base salary plus prorated bonus if terminated without cause or for good reason outside CIC period.","No familial relationship with directors/officers; at-will employment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229472,"accession_number":"0000950170-24-044593","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2024-04-16T23:59:59+00:00","items":["1.01","3.02","5.03","7.01","8.01","9.01"],"status":"ready","headline":"Cullinan raises $280M, pivots to autoimmune with promising CLN-978 data; cash runway into 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$280M private placement at $19/share; pre-funded warrants $18.999; extends cash runway into 2028.","Strategic pivot to autoimmune diseases; first indication systemic lupus erythematosus (SLE); IND planned Q3 2024.","CLN-978 Phase 1 B-NHL data: 1 complete response, rapid B cell depletion, low-grade CRS, no ICANS.","Name change to Cullinan Therapeutics (Nasdaq: CGEM); reflects expanded focus beyond oncology.","Enrollment in B-NHL study discontinued to focus on autoimmune development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248029,"accession_number":"0000950170-24-031140","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cullinan Oncology reports Q4 2023 net loss of $25.6M; CFO Trigilio to depart Mar 29","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY 2023 was $155.1M vs income of $109.2M in 2022; Q4 loss $25.6M.","Cash and investments $468.3M; runway expected into H2 2026.","On track to report CLN-619 combo/monotherapy data at a medical meeting in Q2 2024.","Received FDA IND clearance for CLN-619 in multiple myeloma; exploring CLN-978 in autoimmune diseases.","CFO Jeff Trigilio to depart effective March 29, 2024, with transition support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248028,"accession_number":"0000950170-24-002745","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Cullinan Oncology reports $468.3M cash as of Dec 31, 2023; runway into H2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Unaudited cash, equivalents, investments, and interest receivable totaled $468.3M as of Dec 31, 2023.","Company expects cash runway into second half of 2026 under current operating plan.","Preliminary figure subject to change upon completion of financial closing procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248027,"accession_number":"0000950170-24-002936","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K/A","filed_at":"2024-01-08T23:59:59+00:00","items":["2.01","2.02"],"status":"ready","headline":"Cullinan Oncology reports $468.3M cash; runway into H2 2026 unchanged","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited cash, equivalents, investments, and interest receivable totaled $468.3M as of Dec 31, 2023.","Cash runway reaffirmed through second half of 2026 based on current operating plan.","Amendment corrects original 8-K filing item number from 2.01 to 2.02; no other changes.","Preliminary estimate subject to completion of quarter-end financial close procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265482,"accession_number":"0000950170-23-060673","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cullinan Oncology reports Q3 net loss of $39.2M; cash runway extends to H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $481.9M at Sept 30, 2023; runway extended into H2 2026 from prior into 2026, driven by $38M ATM net proceeds and higher interest income.","Net loss $39.2M in Q3 vs $32.2M in Q2; R&D expenses $33.8M (up from $27.4M) on higher manufacturing and clinical costs.","CLN-619 (MICA/B) monotherapy clinical activity observed; combination dose escalation enrollment completed; initial data expected Q2 2024.","Zipalertinib (EGFR ex20ins) Phase 2b REZILIENT1 enrollment completion targeted by end 2024; Phase 3 REZILIENT3 initiated.","CLN-978 (CD19xCD3) first patient dosed in Phase 1 for R/R B-NHL; CLN-617 first-in-human expected by year-end 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282683,"accession_number":"0000950170-23-040950","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cullinan Oncology Q2 2023: Net loss $32.2M; cash $512.1M; pipeline advances with Phase 3 start","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $512.1M as of June 30, 2023; expected runway into 2026.","Net loss $32.2M in Q2 2023 vs $58.1M in Q1 2023; R&D expenses decreased due to one-time $25M upfront in Q1.","Phase 3 REZILIENT-3 study of zipalertinib in EGFR exon20 NSCLC first-line initiated in August 2023.","CLN-619 monotherapy expansion cohorts in endometrial and cervical cancers initiated; first patient dosed in Phase 1 CLN-978 for R/R B-NHL.","IND cleared for CLN-617; Phase 1 study expected to start in H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301960,"accession_number":"0000950170-23-027958","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2023-06-14T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Cullinan Oncology transitions CSO Patrick Baeuerle to advisor; stockholders elect directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Baeuerle transitions from Chief Scientific Officer to Co-Founder & Chief Scientific Advisor, effective June 8, 2023.","Consulting agreement: $40,556 monthly, max $480,000/year, with bonus opportunity (40% in 2023, 25% thereafter).","Stockholders elected Nadim Ahmed (28,651,746 votes for) and Stephen Webster (21,598,415 for) as Class III directors.","Ratification of KPMG LLP as independent auditor for FY2023 approved with 34,563,271 votes for.","Term of consulting agreement runs through Dec 31, 2024, with annual auto-renewal; either party may terminate on 180 days notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301959,"accession_number":"0001193125-23-154347","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2023-05-25T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cullinan reports Phase 1 CLN-619 data: 1 CR, 2 PRs in solid tumors; expansion in endometrial/cervical cancers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CLN-619 monotherapy showed 1 complete response (parotid gland cancer) and 2 unconfirmed partial responses (endometrial cancer) in heavily pre-treated patients.","54% of patients had prior checkpoint inhibitor therapy; responses observed in patients who progressed on prior CPI.","No dose-limiting toxicities across 0.1-10 mg/kg doses; infusion reactions Grade 1/2 only with pre-medication.","Based on gynecologic activity, company will initiate monotherapy expansion cohorts in endometrial and cervical cancers.","Phase 1 trial continues enrolling monotherapy and combination (with pembrolizumab) arms; future results to be shared."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301958,"accession_number":"0001193125-23-142014","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cullinan Oncology Q1 net loss $58.1M; cash $503.5M; zipalertinib dose change","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $58.1M for Q1 2023 vs $27.1M in Q4 2022; R&D expenses $52.1M including $25M upfront for CLN-418 license.","Cash, equivalents, investments $503.5M as of March 31, 2023; runway into 2026.","Zipalertinib pivotal study now enrolling at 100mg BID only; 150mg BID cohort discontinued per safety review.","First clinical data for CLN-049 (EHA) and CLN-619 (ASCO) to be presented mid-2023.","Licensed CLN-418 from Harbour Biomed for $25M upfront plus up to $563M in milestones and royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321688,"accession_number":"0001193125-23-065289","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2023-03-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cullinan Oncology reports Q4 net loss of $27.1M; licenses CLN-418; cash runway into 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $550.1M as of Dec 31, 2022; cash runway expected into 2026.","Licensed U.S. rights to CLN-418 from Harbour Biomed for $25M upfront, up to $563M milestones plus royalties.","Q4 net loss before noncontrolling interest $27.1M; full-year net income $109.2M due to gain on sale of Cullinan Pearl.","IND clearance for CLN-978 (CD19xCD3) in Jan 2023; IND filed for CLN-617 (IL-12/IL-2) in Feb 2023.","Initial clinical data for CLN-049 and CLN-619 expected mid-2023; pivotal study for zipalertinib initiated Q4 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321687,"accession_number":"0001193125-23-036285","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2023-02-14T23:59:59+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"Cullinan licenses U.S. rights to B7H4 x 4-1BB bispecific CLN-418 from Harbour; cash runway into 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront $25M; up to $148M dev/reg milestones + $415M sales milestones plus tiered royalties up to high teens.","CLN-418/HBM7008 is a clinical-stage (Phase 1) B7H4 x 4-1BB bispecific immune activator for solid tumors.","Cash and investments $550M at end 2022; after $25M upfront would be $525M; expects cash to last into 2026.","Company expects to have six clinical-stage assets in pipeline by end 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321686,"accession_number":"0001193125-23-011002","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2023-01-19T23:59:59+00:00","items":["3.02","5.03","9.01"],"status":"ready","headline":"Cullinan Oncology exchanges 6.5M common shares for Series A convertible preferred held by BVF funds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchanged 6,475,000 common shares for 647,500 Series A convertible preferred (10:1 conversion ratio).","Issued under Section 3(a)(9) exemption; no commissions paid.","Preferred shares have no voting rights; conversion limited to initial 9.99% beneficial ownership cap.","Post-exchange common outstanding: 39,324,370; preferred convertible into up to 6,457,000 common shares.","Transaction closed Jan 19, 2023 with Biotechnology Value Fund L.P. and affiliates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339783,"accession_number":"0001193125-22-283667","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cullinan Oncology reports Q3 net loss $24.9M; initiates pivotal zipalertinib study","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Initiated pivotal study for zipalertinib in EGFR exon 20 NSCLC; cohort to evaluate 150 mg BID with food.","Increased ownership in MICA (CLN-619) from 54% to 92% for $30.7M cash.","Cash and investments $606.7M at Sept 30, 2022; runway extends beyond key milestones.","Net loss before noncontrolling interest $24.9M; R&D expenses $19.7M, G&A $10.1M.","Appointed Jacquelyn Sumer as CLO and Dr. David Ryan to Board; IND filings for CLN-617, CLN-978 on track for H1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":2.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339782,"accession_number":"0001193125-22-275466","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"David P. Ryan appointed to board; Ansbert Gadicke resigns as director at Cullinan Oncology","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David P. Ryan, M.D. appointed as Class II director effective Nov 1, 2022.","Dr. Ryan brings over 20 years of oncology experience; Clinical Director at MGH Cancer Center since 2012.","Received option grant with $250,000 fair value, vesting one-third annually over three years.","Ansbert Gadicke, M.D. resigned as director effective Nov 1, 2022; no disagreement with Company.","Dr. Ryan appointed to Compensation Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339781,"accession_number":"0001193125-22-267965","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2022-10-25T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Cullinan Oncology increases ownership in MICA subsidiary to 92% for $30.7M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchased 14.97M shares from Avalon Ventures and Bregua Corp at $2.05/share, totaling $30.7M.","Ownership in MICA (holder of CLN-619 rights) increased from 54% to 92%.","MICA holds worldwide rights to CLN-619, a monoclonal antibody targeting MICA/MICB pathway.","Phase I trial of CLN-619 (monotherapy + combo with checkpoint inhibitor) on track for initial data in mid-2023.","Myeloma Investment Fund (MMRF) retained its existing ownership stake in MICA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357106,"accession_number":"0001193125-22-216798","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cullinan Oncology reports Q2 2022 net income of $174.1M, cash runway through 2026 after Taiho deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $656M as of June 30, 2022; expected to fund operations through 2026.","Completed strategic collaboration with Taiho for CLN-081; received $275M upfront, eligible for $130M milestones.","Net income of $174.1M in Q2 2022 vs net loss of $12.9M in Q1 2022, driven by $276.8M gain on sale of Cullinan Pearl.","Updated CLN-081 data at ASCO: median DOR >21 months, median PFS 12 months, 41% confirmed ORR at 100mg BID.","Initial clinical data for CLN-619 and CLN-049 expected by mid-2023; IND filings for CLN-617, CLN-978 in H1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":3.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375670,"accession_number":"0001193125-22-182838","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2022-06-27T23:59:59+00:00","items":["1.01","2.01","7.01","9.01"],"status":"ready","headline":"Cullinan Oncology closes $275M sale of Cullinan Pearl to Taiho; co-development deal for CLN-081","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash payment of $275M from Taiho; potential $130M in regulatory milestones for CLN-081/TAS6417.","Taiho obtains exclusive global rights outside U.S.; companies co-develop and co-commercialize CLN-081 in U.S.","U.S. profits and development costs split 50/50 between Cullinan and Taiho; Cullinan retains co-commercialization option.","Deal includes sale of Cullinan Pearl Corp., which holds ex-Japan rights to CLN-081/TAS6417."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375669,"accession_number":"0001193125-22-181528","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2022-06-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cullinan Oncology shareholders re-elect Gadicke and Rosenberg as directors, ratify KPMG","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Ansbert Gadicke elected with 27,033,605 votes for, 10,667,725 withheld, 4,141,978 broker non-votes.","Anthony Rosenberg elected with 27,229,454 votes for, 10,471,876 withheld, same broker non-votes.","KPMG ratified as independent auditor for FY2022: 41,825,399 for, 12,030 against, 5,879 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375668,"accession_number":"0001193125-22-150830","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2022-05-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cullinan Oncology Q1 net loss $12.9M; Taiho deal adds $275M, extends cash runway through 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $410M at March 31, 2022; $685M including $275M Taiho upfront; runway extended to 2026.","Net loss $12.9M vs $34.2M Q4 2021; R&D expense $24.5M, G&A $8.1M.","CLN-081 co-development deal with Taiho: $275M upfront, up to $130M milestones, 50/50 US profit share.","CLN-081 granted Breakthrough Therapy Designation; 41% confirmed ORR at 100mg BID; ASCO oral June 2022.","IND filings for CLN-617 and CLN-978 on track for H1 2023; CLN-049 and CLN-619 Phase 1 dosing ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375667,"accession_number":"0001193125-22-147984","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"Cullinan Oncology sells Cullinan Pearl to Taiho for $275M; co-develop CLN-081 in U.S.","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Taiho will acquire Cullinan Pearl for $275M upfront, plus up to $130M in regulatory milestones.","Cullinan and Taiho will co-develop and co-commercialize CLN-081 (EGFR exon20 inhibitor) in the U.S., sharing profits 50/50.","As of March 31, 2022, cash and investments were $410M; including $275M upfront, pro forma $685M.","Cash runway extended to 2026 from prior guidance of 2024, excluding potential milestones and U.S. profit share.","Acquisition expected to close in Q2 2022, subject to HSR and other customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394003,"accession_number":"0001193125-22-077804","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2022-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cullinan Oncology reports Q4 2021 net loss of $34.4M; cash $430.9M through 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $34.4M in Q4 2021 vs $18.4M in Q3 2021; FY 2021 net loss $67.5M vs $59.5M in FY 2020.","Cash and investments $430.9M as of Dec 31, 2021, expected to fund operations through 2024.","CLN-081 Phase 1/2a data: 39% confirmed PR at 100mg BID; median DOR >15 months, PFS 12 months.","CLN-081 received FDA Breakthrough Therapy Designation in Jan 2022; regulatory update expected Q1 2022.","CLN-049 and CLN-619 first-in-human dosing initiated Dec 2021; initial data expected by mid-2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-03-17T23:59:59+00:00|394003"}